p.112 抽出テキスト

Diagnosis and management of ICI-associated pericarditis Multimodality CV imaging (echocardiography, CMR + CT), ECG and measurement of cardiac biomarkers are recommended to confirm the diagnosis, assess the haemodynamic consequences of pericardial disease, and rule out associated myocarditis. I C

Prednisolone and colchicine are recommended for patients with ICI-associated pericarditis. I C

Interruption of ICI treatment in patients with confirmed ICI-associated pericarditis with moderate-to-severe pericardial effusion is recommended. I C

A multidisciplinary discussion is recommended before restarting ICI treatment. I C

Recommendation Table 39 for end-of-cancer therapy cardiovascular risk assessment

Educating and supporting patients with cancer to make appropriate healthy lifestyle choices is recommended. I C

Education is recommended for patients with cancer regarding recognition for early signs and symptoms of CVD. I C

CVRF assessment is recommended during the first year after cancer therapy and thereafter according to the 2021 ESC Guidelines on CVD prevention in clinical practice. I B In asymptomatic high-risk patients, echocardiography and cardiac serum biomarkers are recommended at 3 and 12 months after completion of cancer therapy. I B Cardiology referral is recommended in patients with cancer with new cardiac symptoms or new asymptomatic abnormalities in echocardiography and/or cardiac serum biomarkers at the end of therapy assessment. I C

Long-term continuation of cardiac medication is recommended in patients who develop severe CTRCD during cancer therapy. I C

CV follow-up and treatment optimization is recommended in patients who developed TKI-mediated hypertension during cancer therapy. I C

CV follow-up and treatment optimization is recommended in patients who developed vascular toxicities during cancer therapy. I C

ECG follow-up is recommended in patients who developed QT lengthening or LQTS during cancer therapy. I C

Recommendation Table 40 for cardiovascular surveillance in asymptomatic adults who are childhood and adolescent cancer survivors Education of adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including the heart and their healthcare providers regarding their increased CV risk is recommended. I B Annual screening for modifiable CVRF is recommended in adults who are childhood and adolescent CS treated with anthracyclines, mitoxantrone, and/or RT to a volume including the heart. I C

CV assessment is recommended in female childhood and adolescent CS prior to pregnancy or in the first trimester. I C

Recommendation Table 41 for cardiovascular surveillance in asymptomatic adult cancer survivors Annual CV risk assessment, including ECG and NP, and CVRF management is recommended in CS who were treated with a potentially cardiotoxic cancer drug or RT. I B

CV toxicity risk restratification is recommended 5 years after therapy to organize long-term follow-up. I C

Recommendation Table 42 for adult cancer survivors who develop cancer therapy-related cardiac dysfunction late after cardiotoxic cancer therapy

ACE-I/ARB and/or beta-blockers are recommended in adult CS with moderate asymptomatic CTRCD. I C

Recommendation Table 43 for adult cancer survivors with coronary artery disease Asymptomatic radiation-induced CAD detected during surveillance Non-invasive stress testing is recommended in asymptomatic CS with new moderate or severe radiation-induced CAD detected on CCTA to guide ischaemia-directed management. I C A MDT discussion is recommended for clinical decision-making in patients with radiation-induced CAD and inducible ischaemia or severe left main CAD. I C

Continued Downloaded from academic.oup.com/eurheartj/article/43/41/4229/6673995 by guest on 07 October 2026